Jonathan Rosenblat

Jonathan D. Rosenblat is a clinical psychiatrist and researcher whose work focuses on rapid-acting and psychedelic-assisted interventions for mood disorders. He has co‑authored clinical studies and evidence syntheses examining intranasal and infusion ketamine protocols, psilocybin‑assisted psychotherapy, and outcomes in treatment‑resistant depression and bipolar depression. His clinical research spans open‑label and controlled trial designs as well as real‑world outcome studies that examine safety, frequency of symptomatic worsening, and predictors of antidepressant response.

Rosenblat has also contributed to methodological and conceptual literature in psychedelic science, including syntheses of serotonergic psychedelics for depression and papers addressing common problems in psychedelic research and publication. His published work frequently intersects clinical trial methodology, translational neuropsychopharmacology, and ethical/rigour considerations for advancing psychedelic therapeutics in psychiatry.